Research programme: YSCMA monoclonal antibodies - Y's Therapeutics

Drug Profile

Research programme: YSCMA monoclonal antibodies - Y's Therapeutics

Alternative Names: AntCyc; YSCMA programme; YSCMA-1L; YSCMA-3L; YSCMA-ATL; YSCMA-GV

Latest Information Update: 04 Nov 2009

Price : $50

At a glance

  • Originator Ys Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 04 Nov 2009 Preclinical development is ongoing in Japan
  • 13 Aug 2009 Y's Therapeutics is seeking out-licensing opportunities & co-development partners for its YSCMA programme (http://www.ysthera.com,
  • 19 Jul 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top